50
Participants
Start Date
April 18, 2017
Primary Completion Date
May 6, 2021
Study Completion Date
May 6, 2021
Argatroban
"Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT \> 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible."
Herz-Kreislauf-Zentrum Klinikum Hersfeld-Rotenburg, Rotenburg an der Fulda
University Hospital Frankfurt, Frankfurt am Main
Lead Sponsor
Mitsubishi Tanabe Pharma GmbH
INDUSTRY